NEW YORK, Sept. 12, 2016 /PRNewswire/ -- BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, including a Phase 3 immuno-oncology compound, Plinabulin, and strong pipeline in collaboration with the Fred Hutchinson Cancer Research Center, announced today that Chief Medical Officer, Ramon Mohanlal, M.D., Ph.D., will present an update on the Company's Phase 3 Plinabulin trial in chemotherapy-induced Neutropenia at the BioPharm America conference that will take place on Sept. 13 through 15, 2016, in Boston, MA.
"BeyondSpring is developing Plinabulin separately as both an anti-cancer agent and to prevent chemotherapy-induced Neutropenia," said Dr. Mohanlal. "Neutropenia is the reduction of white blood cells that are key components of the immune system and frequently results from treatment with chemotherapy. Patients with Neutropenia are more susceptible to bacterial infections, and this condition, Febrile Neutropenia, carries a high risk for mortality and often requires hospitalization. It also often necessitates a reduction or delay of the chemotherapy that caused Neutropenia, leaving patients with suboptimal anti-cancer treatment."
Dr. Mohanlal continued, "Plinabulin has the potential to be an effective, safe – with much less bone pain – cost-effective, and convenient alternative to G-CSF for the prevention of chemotherapy-induced Neutropenia. A clinical development program with Plinabulin in the prevention of chemotherapy-induced Neutropenia has been initiated, and a global Phase 3 trial with Plinabulin in combination with Docetaxel in non-small cell lung cancer is currently underway. BeyondSpring also recently announced patient enrollment in China." Dr. Mohanlal's oncology presentation at BioPharm America will take place on Sept. 15, 2016, at 1:30 p.m. ET in Salon C, Level 4.
About BeyondSpring Pharmaceuticals
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring has advanced its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer. The Company is also planning a Phase 3 clinical trial for Plinabulin in the prevention of docetaxel-induced Neutropenia. BeyondSpring's experienced management team brought a combined 30+ drugs to market.
Plinabulin is an innovative small molecule agent that has multiple mechanism of action, with immune enhancing mechanism, tumor vasculature targeting and activating JNK pathway to induce cancer cell apoptosis.
SOURCE BeyondSpring Pharmaceuticals